Ignite Creation Date:
2024-05-05 @ 6:39 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00520390
Status:
COMPLETED
Last Update Posted:
2010-04-02
First Post:
2007-08-23
Brief Title:
A Phase I Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma EZN-2208-02
Sponsor:
Enzon Pharmaceuticals Inc
Organization:
Enzon Pharmaceuticals Inc
Organization Data
Organization:
Enzon Pharmaceuticals Inc
Class:
INDUSTRY
Study ID:
EZN-2208-02
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Enzon Pharmaceuticals Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None